Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III t... Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.13 | -9.55882352941 | 1.36 | 1.82 | 1.22 | 1248242 | 1.30398929 | CS |
| 4 | -0.87 | -41.4285714286 | 2.1 | 2.33 | 1.22 | 485676 | 1.40277967 | CS |
| 12 | -0.33 | -21.1538461538 | 1.56 | 2.33 | 1.22 | 289151 | 1.58011918 | CS |
| 26 | -1.52 | -55.2727272727 | 2.75 | 3.12 | 1.22 | 357647 | 1.62485858 | CS |
| 52 | -0.84 | -40.5797101449 | 2.07 | 4.69 | 1.22 | 224008 | 1.86273363 | CS |
| 156 | -10.47 | -89.4871794872 | 11.7 | 11.7 | 1.22 | 147112 | 4.55379764 | CS |
| 260 | -17.07 | -93.2786885246 | 18.3 | 43.9 | 1.22 | 661917 | 20.10975772 | CS |
| Nessuna Discussione Trovata |
| Crea Discussione |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
